You are here

  • Home
  • Archive
  • Volume 109, Issue 20
  • Correspondence on ‘Prevalence of pulmonary hypertension in aortic regurgitation and its influence on outcomes’ by Ratwatte et al

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Correspondence
Correspondence on ‘Prevalence of pulmonary hypertension in aortic regurgitation and its influence on outcomes’ by Ratwatte et al
  1. Hector I Michelena1,
  2. Vidhu Anand1,
  3. Maurice Enriquez-Sarano2,
  4. Patricia A Pellikka1
  1. 1 Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA
  2. 2 Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA
  1. Correspondence to Dr Hector I Michelena, Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, MN 55905, USA; michelena.hector{at}mayo.edu

http://dx.doi.org/10.1136/heartjnl-2023-323347

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor The study by Ratwatte et al 1 is a large national cohort retrospective assessment of mortality according to severity of pulmonary hypertension (pHTN) in patients with ≥moderate aortic regurgitation (AR); the authors should be commended for building such a large national database. While pHTN is associated with excess mortality in any clinical context,2 the relevant approach is to causally link the pHTN to the specific clinical context examined, in this case clinically significant AR, in order to infer its potential role in the management of AR. For this purpose, fundamental questions must be addressed: (1) Is this a representative cohort of patients with clinically significant AR? (2) Is the pHTN the result of advanced untreated AR? and (3) Do we have sufficient information on the consequences of AR and patient comorbidity burden to draw sound clinical …

    View Full Text

    Footnotes

    • Twitter @michelenahector, @sarano_maurice, @pattypellikka

    • Contributors All authors have contributed to the intellectual content of the paper, grafting and revision of the paper and have approved the final submission.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles